BACKGROUND: Protein 4.2 deficiency caused by mutations in the EPB42 gene results in hereditary spherocytosis with characteristic alterations of CD47, CD44 and RhAG. We decided to investigate at which stage of erythropoiesis these hallmarks of protein 4.2 deficiency arise in a novel protein 4.2 patient and whether they cause disruption to the band 3 macrocomplex. DESIGN AND METHODS: We used immunoprecipitations and detergent extractability to assess the strength of protein associations within the band 3 macrocomplex and with the cytoskeleton in erythrocytes. Patient erythroblasts were cultured from peripheral blood mononuclear cells to study the effects of protein 4.2 deficiency during erythropoiesis. RESULTS: We report a patient with two novel mutations in EPB42 resulting in complete protein 4.2 deficiency. Immunoprecipitations revealed a weakened ankyrin-1-band 3 interaction in erythrocytes resulting in increased band 3 detergent extractability. CD44 abundance and its association with the cytoskeleton were increased. Erythroblast differentiation revealed that protein 4.2 and band 3 appear simultaneously and associate early in differentiation. Protein 4.2 deficiency results in lower CD47, higher CD44 expression and increased RhAG glycosylation starting from the basophilic stage. The normal downregulation of CD44 expression was not seen during protein 4.2(-) erythroblast differentiation. Knockdown of CD47 did not increase CD44 expression, arguing against a direct reciprocal relationship. CONCLUSIONS: We have established that the characteristic changes caused by protein 4.2 deficiency occur early during erythropoiesis. We postulate that weakening of the ankyrin-1-band 3 association during protein 4.2 deficiency is compensated, in part, by increased CD44-cytoskeleton binding.
BACKGROUND: Protein 4.2 deficiency caused by mutations in the EPB42 gene results in hereditary spherocytosis with characteristic alterations of CD47, CD44 and RhAG. We decided to investigate at which stage of erythropoiesis these hallmarks of protein 4.2 deficiency arise in a novel protein 4.2 patient and whether they cause disruption to the band 3 macrocomplex. DESIGN AND METHODS: We used immunoprecipitations and detergent extractability to assess the strength of protein associations within the band 3 macrocomplex and with the cytoskeleton in erythrocytes. Patient erythroblasts were cultured from peripheral blood mononuclear cells to study the effects of protein 4.2 deficiency during erythropoiesis. RESULTS: We report a patient with two novel mutations in EPB42 resulting in complete protein 4.2 deficiency. Immunoprecipitations revealed a weakened ankyrin-1-band 3 interaction in erythrocytes resulting in increased band 3 detergent extractability. CD44 abundance and its association with the cytoskeleton were increased. Erythroblast differentiation revealed that protein 4.2 and band 3 appear simultaneously and associate early in differentiation. Protein 4.2 deficiency results in lower CD47, higher CD44 expression and increased RhAG glycosylation starting from the basophilic stage. The normal downregulation of CD44 expression was not seen during protein 4.2(-) erythroblast differentiation. Knockdown of CD47 did not increase CD44 expression, arguing against a direct reciprocal relationship. CONCLUSIONS: We have established that the characteristic changes caused by protein 4.2 deficiency occur early during erythropoiesis. We postulate that weakening of the ankyrin-1-band 3 association during protein 4.2 deficiency is compensated, in part, by increased CD44-cytoskeleton binding.
Authors: Ashley M Toye; Sandip Ghosh; Mark T Young; Graham K Jones; Richard B Sessions; Martine Ramaugé; Philippe Leclerc; Joyoti Basu; Jean Delaunay; Michael J A Tanner Journal: Blood Date: 2005-02-03 Impact factor: 22.113
Authors: H Wada; A Kanzaki; A Yawata; T Inoue; M Kaku; M Takezono; T Sugihara; O Yamada; Y Yawata Journal: Exp Hematol Date: 1999-01 Impact factor: 3.084
Authors: Gerhard Rank; Rosemary Sutton; Vikki Marshall; Rachel J Lundie; Jacinta Caddy; Tony Romeo; Kate Fernandez; Matthew P McCormack; Brian M Cooke; Simon J Foote; Brendan S Crabb; David J Curtis; Douglas J Hilton; Benjamin T Kile; Stephen M Jane Journal: Blood Date: 2009-01-28 Impact factor: 22.113
Authors: Nigel E J Appleford; Kim Wilson; Fiona Houston; Lesley J Bruce; Alex Morrison; Matthew Bishop; Kevin Chalmers; Gino Miele; Edwin Massey; Chris Prowse; Jean Manson; Robert G Will; Michael Clinton; Ian MacGregor; David J Anstee Journal: Transfusion Date: 2008-05-22 Impact factor: 3.157
Authors: Adrienne M Hammill; Mary A Risinger; Clinton H Joiner; Mehdi Keddache; Theodosia A Kalfa Journal: Br J Haematol Date: 2011-01-31 Impact factor: 6.998
Authors: Timothy J Satchwell; Amanda J Bell; Bethan R Hawley; Stephanie Pellegrin; Kathryn E Mordue; Cees Th B M van Deursen; Nicole Heitink-Ter Braak; Gerwin Huls; Mathie P G Leers; Eline Overwater; Rienk Y J Tamminga; Bert van der Zwaag; Elisa Fermo; Paola Bianchi; Richard van Wijk; Ashley M Toye Journal: Haematologica Date: 2016-05-31 Impact factor: 9.941
Authors: Steven Heshusius; Esther Heideveld; Patrick Burger; Marijke Thiel-Valkhof; Erica Sellink; Eszter Varga; Elina Ovchynnikova; Anna Visser; Joost H A Martens; Marieke von Lindern; Emile van den Akker Journal: Blood Adv Date: 2019-11-12
Authors: Jaroslaw Cendrowski; Marta Kaczmarek; Michał Mazur; Katarzyna Kuzmicz-Kowalska; Kamil Jastrzebski; Marta Brewinska-Olchowik; Agata Kominek; Katarzyna Piwocka; Marta Miaczynska Journal: Elife Date: 2020-08-14 Impact factor: 8.140